NasdaqGS:NTRABiotechs
How Investors May Respond To Natera (NTRA) Deepening Its MRD Role In Immunotherapy And Cancer Care
In recent days, Kupando Therapeutics announced a collaboration using Natera’s Latitude tissue-free MRD assay to monitor ctDNA dynamics in a Phase 1 trial of its KUP-101 immunotherapy across advanced skin cancers, while Natera also reported higher second-quarter 2026 revenue of US$752.75 million and a reduced net loss of US$66.97 million versus a year earlier.
These developments, alongside Natera’s raised 2026 revenue guidance, PMDA submission for Signatera in muscle-invasive bladder cancer,...